Eczema drug trial aims to soothe itch and clear skin for 1,000 patients
NCT ID NCT07276620
First seen Jan 07, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests an approved eczema drug, ivarmacitinib, in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (a type of eczema). Researchers want to see how well it reduces itching and clears skin rashes over 16 weeks, and to gather safety information. Participants continue their usual care and no extra visits are expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.